|Bid||38.00 x 800|
|Ask||43.22 x 1200|
|Day's Range||37.67 - 40.80|
|52 Week Range||25.01 - 45.80|
|Beta (5Y Monthly)||0.89|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||47.11|
Shares of PTC stock continued a seven-day run Thursday on promising test results for its Duchenne muscular dystrophy treatment.
PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call Tuesday, June 21st at 8:00 a.m. E.T. to review topline results from Study 041 of Translarna™ (ataluren) in patients with nonsense mutation Duchenne muscular dystrophy. The call will be accompanied by a slide presentation which can be accessed through our online webcast.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the election of Alethia Young to the company's Board of Directors. Ms. Young has more than 20 years of experience in healthcare and biotech equity research and investing. She is currently the Chief Financial Officer of Graphite Bio where she oversees the company's finance, investor relations and corporate communications functions, and plays a key role in overall corporate strategy.